BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Investor Presentation
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Balaxi Pharmaceuticals reported FY26 consolidated revenue of ₹270.17 crore, down 7.7% YoY from ₹292.56 crore in FY25, impacted by extended working capital cycles in Angola's institutional business. Despite lower revenues, gross profit margins improved to 44.2% from 43.4%, reflecting better business mix and disciplined product selection. However, EBITDA dropped 66.1% to ₹11.35 crore (4.2% margin vs 11.5% in FY25), and PAT fell 94.3% to just ₹1.42 crore. LATAM delivered strong growth with 11% YoY increase to ₹111.29 crore. The company secured 49 new product registrations taking the total portfolio to 964 products across seven countries. A major milestone was achieved with receipt of the Manufacturing Licence for its first pharmaceutical formulation facility in Hyderabad, which is expected to drive backward integration and margin expansion over the medium term. The company also plans to discontinue its ancillary Building Hardware business to sharpen focus on pharmaceuticals.
The stock may face pressure in the short term due to severely compressed profitability (PAT margin fell to 0.5% from 8.6%), though the strategic manufacturing facility and LATAM growth momentum could provide medium-term recovery catalysts. Improved gross margins indicate better pricing power and product mix, a positive signal.